{"organizations": [], "uuid": "684270f7a01a6543225f24711d5495ff006038c7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/03/globe-newswire-iovance-biotherapeutics-to-host-first-quarter-2018-financial-results-conference-call-and-webcast-on-thursday-may-10-2018.html", "country": "US", "domain_rank": 767, "title": "Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-03T16:01:00.000+03:00", "replies_count": 0, "uuid": "684270f7a01a6543225f24711d5495ff006038c7"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/03/globe-newswire-iovance-biotherapeutics-to-host-first-quarter-2018-financial-results-conference-call-and-webcast-on-thursday-may-10-2018.html", "ord_in_thread": 0, "title": "Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "calif.", "sentiment": "none"}, {"name": "san carlos", "sentiment": "none"}], "organizations": [{"name": "iovance biotherapeutics", "sentiment": "neutral"}, {"name": "iovance biotherapeutics, inc.", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN CARLOS, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2018 financial and operating results on Thursday, May 10, 2018. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.\nIn order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 2995797. The live webcast can be accessed under “News & Events” in the “Investors” section of the Company’s website at http://www.iovance.com/ or you may use the link: https://edge.media-server.com/m6/p/ouykqu6a .\nA replay of the call will be available from May 10, 2018 at 7:30 p.m. ET to May 17, 2018 at 8:30 p.m. ET. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 2995797. The archived webcast will be available for thirty days in the Investors section of Iovance Biotherapeutics’ website at http://www.iovance.com/ .\nAbout Iovance Biotherapeutics, Inc.\nIovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer, and locally advanced or metastatic non-small cell lung cancer. For more information, please visit http://www.iovance.com .\nInvestor Contact:\nSarah McCabe\nStern Investor Relations, Inc.\n212-362-1200\nsarah@sternir.com\nMedia Contact:\nEvan Smith\nFTI Consulting\n212-850-5622\nevan.smith@fticonsulting.com\nSource:Iovance Biotherapeutics, Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/d0986bd6-4603-4e31-8ed1-f23b3e123605", "http://www.iovance.com/", "https://edge.media-server.com/m6/p/ouykqu6a"], "published": "2018-05-03T16:01:00.000+03:00", "crawled": "2018-05-03T18:09:14.020+03:00", "highlightTitle": ""}